Saltar al contenido
Merck
Todas las fotos(2)

Documentos

916978

Sigma-Aldrich

BocA1V2PF1

≥95%

Sinónimos:

((S)-2-((S)-2-((tert-Butoxycarbonyl)amino)propanamido)-2-cyclohexylacetyl)-L-prolyl-L-phenylalanine, AVP ligand, IAP E3 ligase lead for protein degrader research, SNIPER building block

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
C30H44N4O7
Peso molecular:
572.69
UNSPSC Code:
41116105
NACRES:
NA.22

ligand

BocA1V2PF1

Quality Level

100

assay

≥95%

form

powder

reaction suitability

reagent type: ligand

functional group

carboxylic acid

storage temp.

2-8°C

SMILES string

C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C3CCCCC3)=O

Categorías relacionadas

Application

BocA1V2PF1 is an in silico-derived inhibitor of apoptosis protein (IAP)-recruiting ligand for targeted protein degradation and SNIPER (specific and non-genetic IAP-dependent protein erasers) development, launched in partnership with ComInnex. Learn more about the novel IAP ligands generated through virtual screening of AVP mimetics in our Technology Spotlight. A C-terminal variant of BocA1V2PF1 is also available as A1V2PF1-NHEt (917222).

BocA1V2PF1 conjugates are also available for degrader synthesis. Browse our full synthesis offering here for streamlining SNIPER and PROTAC® degrader libraries: Degrader Building Blocks
917966 BocA1V2PF1-NHC6-NH2
916706 BocA1V2PF1-NHC10-NH2
916951 BocA1V2PF1-NHPEG1-NH2
917214 BocA1V2PF1-NHPEG3-NH2

Technology Spotlight: Degrader Building Blocks with Inhibitor of Apoptosis Protein (IAP) In Silico-Derived Ligands

Other Notes

In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)

SNIPERs−Hijacking IAP activity to induce protein degradation

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Referencia del producto
Descripción
Precios

917931

A1V2PF2-NHEt-C6-NH2

916684

A1V2PF2-NHEt-C10-NH2, ≥95%

917680

BocA1V1PF2-OPEG3-NH2 hydrochloride

917966

BocA1V2PF1-NHC6-NH2

917702

A1V2PF1-NHEt-PEG3-NH2

917451

A1V2PF1-NHEt-PEG1-NH2, ≥95%

917974

BocA1V2PF2

917710

A1V1PF2-OEt, ≥95%

917478

BocA1V1PF2, ≥95%

917214

BocA1V2PF1-NHPEG3-NH2, ≥85%

916951

BocA1V2PF1-NHPEG1-NH2

916927

BocA1V1PF2-OC6-NH2 hydrochloride, ≥95%

916676

A1V1PF2-OEt-PEG3-NH2 hydrochloride

917923

A1V1PF2-OEt-PEG1-NH2 hydrochloride

917672

A1V1PF2-OEt-C10-NH2 hydrochloride

917206

A1V2PF1-NHEt-C10-NH2

917184

BocA1V1PF2-OC10-NH2 hydrochloride

916943

A1V2PF1-NHEt-C6-NH2

916692

BocA1V2PF2-NHPEG3-NH2, ≥95%

917427

A1V1PF2-OEt-C6-NH2 hydrochloride

916706

BocA1V2PF1-NHC10-NH2

917435

BocA1V1PF2-OPEG1-NH2 hydrochloride, ≥95%

916978

BocA1V2PF1, ≥95%

917699

BocA1V2PF2-NHC10-NH2, ≥85%

917222

A1V2PF1-NHEt, ≥95%

917958

BocA1V2PF2-NHPEG1-NH2

916714

A1V2PF2-NHEt, ≥95%

917192

A1V2PF2-NHEt-PEG3-NH2, ≥95%

916935

A1V2PF2-NHEt-PEG1-NH2

917443

BocA1V2PF2-NHC6-NH2

919381

CCW16, ≥95%

CIX001

ComInnex IAP Ligand Library

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Tasuku Ishida et al.
SLAS discovery : advancing life sciences R & D, 26(4), 484-502 (2020-11-05)
Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to

Artículos

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Degrader Building Blocks with IAP In Silico-Derived Ligands

Targeted protein degradation reduces disease-relevant proteins in cells using small molecules, hijacking endogenous proteolysis systems.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico